Antiandrogenic therapy can cause coronary arterial disease

Kuan Chou Chen, Chiung Chi Peng, Hsiu Mei Hsieh, Chiung Huei Peng, Chiu Lan Hsieh, Chien Ning Huang, Charng Cherng Chyau, Hui Er Wang, Robert Y. Peng*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

13 Citations (Scopus)


Aim: To study the change of lipid metabolism by antiandrogen therapy in patients with prostate cancer. Materials and methods: We studied with a 2.5 years follow-up the changes in plasma cholesterols (C), triglycerides (TG), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II profiles in 24 patients of mean age 60 years with low risk prostate cancer (stage: T1cN 0M0, Gleason score: 2-5) during treatment with cyproterone acetate (CPA) without surgical management or radiation therapy. Results: Significant decreases of HDL-C, Apo A-I and Apo A-II and an increase of triglyceride levels in VLDL were induced by CPA. After a period of 2.5 years on CPA treatment, four patients out of twenty-four were found to be affected by coronary heart disease. Conclusions: Ischaemic coronary arteriosclerosis with an incidence rate of 16.6% as caused by prolonged CPA therapy is mediated through changes in HDL cholesterol, Apo A-I and Apo A-II profiles, other than the well-known hyperglyceridemic effect caused by estrogen.

Original languageEnglish
Pages (from-to)886-891
Number of pages6
JournalInternational Journal of Urology
Issue number10
Publication statusPublished - 2005 Oct


  • Antiandrogen
  • CAD (coronary arterial disease)
  • CPA (cyproterone acetate)
  • Hormonal therapy
  • Prostate cancer

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Antiandrogenic therapy can cause coronary arterial disease'. Together they form a unique fingerprint.

Cite this